Zhendong Pharmaceutical and Huawei Launch Joint AI Drug Discovery Laboratory
Zhendong Pharmaceutical and Huawei unveiled a joint innovation laboratory for AI-enabled drug discovery at Huawei Connect 2026 in Shanghai on September 17, 2026. The laboratory will focus on target discovery, hit compound discovery, lead compound optimization, and clinical trials, while accelerating the application of Ascend in vertical industry scenarios.
On September 17, 2026, the Huawei Connect 2026 forum titled "Deepening in Pharmaceuticals, Letting Intelligence Take Root" was held in Shanghai. During the forum, Zhendong Pharmaceutical and Huawei held an unveiling ceremony for their joint innovation laboratory for AI-enabled drug discovery.
The joint innovation laboratory will focus on joint research in areas including target discovery, hit compound discovery, lead compound optimization, and clinical trials, and will accelerate breakthroughs in applying Ascend in vertical scenarios.
Why this event matters
The event has a measured impact on 3 industrys. The strongest current signal is positive for Artificial Intelligence, with intensity 50/100 and 65% confidence over a short term horizon.
Artificial Intelligence
- Direction
- positive
- Intensity
- 50
- Confidence
- 65%
- Horizon
- Short term
Pharmaceuticals
- Direction
- positive
- Intensity
- 45
- Confidence
- 60%
- Horizon
- Medium term
Pharmaceutical R&D Services
- Direction
- positive
- Intensity
- 40
- Confidence
- 55%
- Horizon
- Medium term
Impact figures are analytical estimates that combine direction, intensity, confidence and event importance. They are not investment advice.